| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Current Ratio | 2.76 | 5.21 | 11.62 | 8.02 | 12.37 | 20.55 |
| Quick Ratio | 2.76 | 5.21 | 11.62 | 8.02 | 12.37 | 20.55 |
| Debt / Equity | — | — | — | — | — | — |
| ROE | -45.74% | 121.98% | -139.12% | -167.17% | -110.06% | -34.56% |
| ROA | -37.99% | -13.10% | -127.14% | -146.33% | -101.16% | -32.87% |
| Asset Turnover | — | — | — | — | — | — |
| Book Value / Share | 15.05 | -9.85 | 0.20 | 0.66 | 1.74 | 6.08 |
Dogwood Therapeutics Inc. is a biopharmaceutical company engaged in the research and development of innovative drug therapies to address unmet medical needs. The company focuses primarily on the development of novel treatments for rare diseases, leveraging cutting-edge technologies and proprietary platforms. Dogwood Therapeutics aims to bring transformative solutions to patients with limited treatment options, working closely with scientific communities and regulatory bodies to advance its clinical programs. With a robust pipeline of candidates in various stages of clinical trials, the company plays a significant role in the biotechnology industry, contributing to the advancement of medical science and therapeutic innovations. Dogwood Therapeutics strategically collaborates with academic institutions and pharmaceutical companies to enhance its research capabilities and accelerate the development process. In the financial market, the company’s performance is closely monitored by investors keen on the growth potential of its groundbreaking therapies and the impact on healthcare improvements. Dogwood Therapeutics Inc.'s commitment to addressing challenging health conditions underscores its importance in the broader pharmaceutical sector.